Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...
Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's ...
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback